Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DDR SYNVIA

Financiado

Cerrado

Cellular models for human disease alleviation mechanisms and potential therapi...

Cellular models for human disease alleviation mechanisms and potential therapies Various human genetic diseases are caused by defects in the DNA-damage response (DDR). DDR genes protect against cancer, as demonstrated by their somatic mutation or epigenetic silencing being common in cancers. Cancer-specific DD... ver más

31/08/2016

THE CHANCELLOR MAS...

300K€

Presupuesto del proyecto: 300K€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

THE CHANCELLOR MASTERS AND S...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SYNVIA Synthetic viability of homologous recombination deficient ca... 2M€ Cerrado

SYNTRAIN Targeting SYNthetic lethal interactions for new cancer treat... 4M€ Cerrado

DDREAMM Dna Damage REsponse Actionabilities Maps and Mechanisms 9M€ Cerrado

SYNTHLE BRCA Synthetic lethality approaches to BRCA associated cancer 169K€ Cerrado

BIO2013-48933-R LETALIDAD SINTETICA Y BIOLOGIA DE SISTEMAS METABOLICOS PARA... 85K€ Cerrado

GENECADD GEnetic NEtworks as a tool for anti CAncer Drug Development 3M€ Cerrado

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 300K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Various human genetic diseases are caused by defects in the DNA-damage response (DDR). DDR genes protect against cancer, as demonstrated by their somatic mutation or epigenetic silencing being common in cancers. Cancer-specific DDR deregulation is ripe for therapeutic exploitation but clinicians are facing two main problems: accurate identification of such exploitable cancer cell defects and development of resistance mechanisms that render tumours unresponsive to classical or targeted chemotherapies. A promising concept to address these issues is synthetic viability, wherein a combination of gene defects rescues the lethal effects of a single gene change. Recent work in model systems has highlighted the strong potential for synthetic viability screening to identify and understand relationships between DDR (and other) cellular components, thereby providing insights relevant to understanding and treating cancer. Furthermore, such screening approaches could also provide insights into, and suggest new treatment paradigms for, various human genetic diseases. The key objective of this Marie Curie project proposal is to explore synthetic viability principles applied to DDR mechanisms. I will carry out synthetic viability screens for genes whose mutation/loss suppresses cellular defects caused by loss of key DDR proteins. I will then carry out studies to determine whether such suppressors could be exploited as potential targets whose inhibition would alleviate the corresponding hereditary genetic disease, or whose re-activation might selectively re-sensitise cancers to DNA damage or DDR inhibitors. This work should thus not only provide insights into DDR processes and interactions between them, but could also suggest avenues for developing newer and more effective personalized cancer treatments. These studies might also suggest new treatment regimens for human DDR deficiency syndromes, and could provide a platform more broadly applicable to many inherited human diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores